Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.

Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

Neurology. 2014 Jul 8;83(2):134-41. doi: 10.1212/WNL.0000000000000564. Epub 2014 Jun 6.

2.

Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.

Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA; UK Collaborative HIV Cohort (CHIC) study.

Neurology. 2011 Feb 22;76(8):693-700. doi: 10.1212/WNL.0b013e31820d8b0b.

3.

Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score.

Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J; FHDH-ANRS CO4.

Neurology. 2011 Feb 15;76(7):644-51. doi: 10.1212/WNL.0b013e31820c3089. Epub 2011 Jan 19.

PMID:
21248274
4.

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group.

Arch Neurol. 2008 Jan;65(1):65-70. doi: 10.1001/archneurol.2007.31.

5.

Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?

McManus H, Li PC, Nolan D, Bloch M, Kiertiburanakul S, Choi JY, Mulhall B, Petoumenos K, Zhou J, Law M, Brew BJ, Wright E.

HIV Med. 2011 Nov;12(10):610-9. doi: 10.1111/j.1468-1293.2011.00938.x. Epub 2011 Aug 7.

6.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):441-7. doi: 10.3851/IMP2926. Epub 2014 Dec 17.

PMID:
25516553
7.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.

Beardsley J, Le T.

Neurology. 2015 Feb 10;84(6):632. doi: 10.1212/01.wnl.0000461261.51494.39. No abstract available.

PMID:
25666633
8.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

9.

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.

Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R.

AIDS. 2011 Jan 28;25(3):357-65. doi: 10.1097/QAD.0b013e32834171f8.

10.

Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.

Lazarus JR, Rutstein RM, Lowenthal ED.

HIV Med. 2015 Jul;16(6):355-61. doi: 10.1111/hiv.12220. Epub 2015 Jan 21.

11.

The relationship of CPE to HIV dementia: slain by an ugly fact?

Berger JR, Clifford DB.

Neurology. 2014 Jul 8;83(2):109-10. doi: 10.1212/WNL.0000000000000580. Epub 2014 Jun 6. No abstract available.

PMID:
24907235
12.
13.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2012 Aug 24;26(13):1691-705.

14.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

15.

HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?

Marra CM.

Antivir Ther. 2015;20(4):365-7. doi: 10.3851/IMP2951. Epub 2015 Mar 17.

PMID:
25781980
16.

Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score?

Fanjul F, Riveiro-Barciela M, Gonzalez J, Delgado E, Murillas J, Payeras Cifré A, Falcó V, Riera M.

HIV Med. 2013 May;14(5):321-5. doi: 10.1111/hiv.12008. Epub 2012 Dec 6. Review.

17.

Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients.

Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL.

J Neurovirol. 2008 Oct;14(5):418-24. doi: 10.1080/13550280802298112.

18.

Neurocognitive impairment and neuroCART.

Wright E.

Curr Opin HIV AIDS. 2011 Jul;6(4):303-8. doi: 10.1097/COH.0b013e3283477c46. Review.

PMID:
21546833
19.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P.

AIDS. 2014 Feb 20;28(4):493-501. doi: 10.1097/QAD.0000000000000096.

PMID:
24472743
20.

HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.

Cross HM, Combrinck MI, Joska JA.

S Afr Med J. 2013 Sep 18;103(10):758-62. doi: 10.7196/samj.6677.

PMID:
24079630

Supplemental Content

Support Center